#Malaria #Vaccination #GA2 #AttenuatedParasites
Despite decades of efforts, preventive
campaigns, mass distribution of bed nets, and antimalarial treatments,
malaria
continues to claim more than 600,000 lives each year. Children under five years
old represent the majority of these deaths, particularly in high-transmission
areas of sub-Saharan Africa. This situation underscores the limitations of
current tools against a disease that adapts, persists, and resists.
The advent of new vaccines marked a turning
point in the fight against malaria. Deployed in several countries, these
vaccines have helped
reduce severe cases and hospitalizations among children.
However, their
effectiveness remains partial, their duration of protection is
limited, and their implementation depends on
multiple-dose series with
boosters, making their integration into already crowded immunization schedules
complex.
Faced with these challenges, the scientific
community is now aiming for a new goal:
to develop a vaccine capable of
providing effective protection with a single dose, offering durable immunity,
easy administration, and suitability for large-scale deployment. This bold
ambition is now taking shape through the exploration of strategies based on
genetically attenuated live parasites, able to simulate natural infection
without causing disease.
The GA2 vaccine candidate fits into this
dynamic. It is a genetically modified strain of Plasmodium falciparum
designed to block its development in the liver, preventing the emergence of
blood-stage forms that cause symptoms and transmission. This approach would
allow the immune system to detect the parasite early and trigger a robust and
targeted immune response.
The aim of this study is to evaluate whether a
single immunization, performed via bites from mosquitoes infected with the GA2
strain, can induce sterile protection. It also seeks to assess the safety,
tolerability, and immune responses associated with this approach.
One bite, total protection?
In this study, 15 healthy adults with no prior
exposure to malaria were divided into two groups:
- 10
participants received immunization via 50 bites from mosquitoes infected
with the attenuated GA2 parasite;
- 5 others were
exposed to uninfected mosquitoes (placebo).
Six weeks after this single immunization, all
participants underwent a controlled human malaria infection (CHMI) via bites
from mosquitoes carrying wild-type Plasmodium falciparum.
The results show that
9 out of 10 participants
in the GA2 group were completely immunized, with no detectable parasitemia up
to 28 days post-infection. In comparison,
all members of the placebo group
developed infection, with a median onset of 9 days. No serious adverse events
were reported. Only mild reactions such as itching, redness, or slight swelling
at the bite site were observed.
Immunologically, GA2 vaccination induced a
strong and specific cellular response. This was dominated by
polyfunctional
memory CD4+ T cells co-expressing TNF, IL-2, and to a lesser extent IFNγ. These
cells displayed an
effector memory phenotype, appearing as early as two weeks
after immunization and persisting beyond the challenge.
Vδ2+ γδ T cells were
also mobilized, indicating activation of adaptive innate immunity.
No humoral response against blood-stage
antigens (AMA-1, MSP-1) was detected. The observed protection relies
exclusively on
pre-erythrocytic immunity, targeting the parasite before it
invades red blood cells. This feature is critical for
early interruption of the
infection cycle.
Read next: A race against time for a vaccine?
Can a mosquito change the game?
Malaria, a parasitic disease
transmitted by
mosquitoes, remains a major public health burden, particularly in sub-Saharan
Africa. Despite therapeutic advances and preventive strategies, the disease
continues to kill hundreds of thousands each year, mostly children. The current
challenge lies in
developing vaccines that provide strong, long-lasting
protection with simplified logistics. Currently recommended vaccines—RTS,S/AS01
and R21/Matrix-M—require several doses and boosters, and their efficacy remains
incomplete, especially against the infection itself.
The objective of this study was to evaluate a
radically different vaccination approach: a single immunization via bites from
mosquitoes infected with genetically attenuated Plasmodium falciparum
parasites (GA2). The main challenge was to demonstrate that a single exposure
could induce sterile protection against controlled infection. The study shows
that 90% of immunized participants were completely protected, with no severe
side effects. The experimental GA2 vaccine thus stands out from current
standards for its power and simplicity.
However,
several limitations should be noted.
The sample size remains small (15 participants), all malaria-naive, which does
not reflect populations living in endemic areas. Moreover, administration via
mosquito bite, while suitable for the experimental model, is
not feasible for
large-scale public health use. Next steps will require trials in naturally
exposed populations, assessment of viable formulations that can be injected,
and validation of a protocol compatible with broad deployment within a vaccination
program. If these conditions are met,
GA2 could well redefine the standards for
malaria vaccination and mark a major advance in the global fight against this
ancient disease.
Read next: Vaccine vs. SMC: rivals or partners?
